USD10
IKT Shares
About Inhibikase TherapeuticsInhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
USD10
IKT Shares
About Inhibikase TherapeuticsInhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Stats
TRADING WINDOW
Closed
OPENS AT
Apr 17 at 1:30 PM GMT+0
MARKET CAP
$241.62M
OPEN PRICE
$1.73
LOW (1Y)
$1.33
HIGH (1Y)
$2.37
LOW (24H)
$1.72
HIGH (24H)
$1.85
VOLUME (24H)
$1.60M
90.17%
Price history
Time | Price | Change |
|---|---|---|
Today | $1.73 | |
1 Day | $1.72 | |
1 Week | $1.80 | |
1 Month | $1.97 | |
1 Year | $1.89 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
